
    
      This study will evaluate the breadth and potency of HIV-1 neutralizing antibody (nAb)
      responses and examine the safety and tolerability of an HIV gp120 protein vaccine (AIDSVAX®
      B/E) in HIV-uninfected adults diagnosed with Systemic Lupus Erythematosus (SLE) who have
      stable disease.

      All participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.

      Study visits will occur at Months 0, 0.25, 0.5, 1, 1.25, 1.5, 3, 6, 6.25, 6.5, 7.5, 8.5, and
      12. Visits may include physical examinations, blood and urine collection, pregnancy testing,
      HIV testing, risk reduction counseling, assessments, and questionnaires.
    
  